JBIO
Jade Biosciences, Inc.16.04
+0.79+5.18%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
737.91MP/E (TTM)
-Basic EPS (TTM)
-Dividend Yield
0%Recent Filings
8-K
Q4 results, $336M cash runway
Jade Biosciences reported Q4 and full-year 2025 results, posting $93.1M R&D and $20.4M G&A expenses amid pipeline ramp-up, driving $127.4M net loss. Cash hit $336.2M after $180M private placements, funding ops into H1 2028. JADE101 Phase 1 data due Q2 2026; JADE201 FIH trial starts then too. Clinical delays loom.
10-K
FY2025 results
Jade Biosciences posted a $127.4M net loss for FY2025 ended December 31, 2025, up from $47.0M in the prior stub period, driven by $93.1M R&D (up 198% y/y) on CMC, tox studies, and clinical starts for JADE101 (Phase 1 dosing began August 2025). Cash burn hit $94.7M from ops amid $336.2M liquidity post-$205M pre-merger PIPE, $135M October PIPE, $45M December PIPE. No revenue; $20.4M G&A reflects public readiness. Pipeline advances: JADE101 Phase 1 data Q2 2026, JADE201 Phase 1 Q2 2026. Clinical delays from NHP shortages threaten timelines.
8-K
$336M cash funds to 2028
Jade Biosciences disclosed preliminary cash, cash equivalents, and investments of approximately $336 million as of December 31, 2025, expected to fund operations into the first half of 2028. The company outlined 2026 pipeline milestones: JADE101 Phase 1 interim data H1 2026, Phase 2 start mid-2026; JADE201 Phase 1 in Q2 2026; JADE301 preclinical with Phase 1 H1 2027. Cash burn accelerates with trials. Risks include delays and higher costs.
8-K
$45M private placement priced
Jade Biosciences inked a private placement on December 13, 2025, selling 3,214,286 shares at $14.00 each to Biotech Growth N.V., expecting ~$45M gross proceeds before expenses. Closing set for December 16, subject to customary conditions. Funds will fuel R&D, corporate expenses, working capital. Biotech needs cash.
10-Q
Q3 FY2025 results
Jade Biosciences ramped R&D spend to $22.0M in Q3 ended September 30, 2025, up 62% y/y from $13.6M (derived), driving a $27.4M operating loss versus $15.0M last year—yet net loss narrowed to $25.2M from $16.3M on $2.3M interest income. JADE101 hit first-in-human dosing; Phase 1 advances alongside JADE201 tox studies and JADE-003 discovery, all via Paragon deals. Cash burned $61.0M YTD on $190.6M PIPE funding post-April reverse recap; $50.1M cash plus $148.8M investments fund runway. Reverse recap closed April 2025, converting $95.0M notes (12% rate, Dec 2026 maturity). Competition crowds IgAN space.
CLYM
Climb Bio, Inc.
4.62+0.81
FBLG
FibroBiologics, Inc.
0.24-0.02
IMA
ImageneBio, Inc.
6.25+0.08
JSPR
Jasper Therapeutics, Inc.
1.71+0.07
PALI
Palisade Bio, Inc.
1.72-0.09
QTTB
Q32 Bio Inc.
2.88-0.17
THAR
Tharimmune, Inc.
2.41+0.01
WHWK
Whitehawk Therapeutics, Inc.
2.40+0.04
ZBIO
Zenas BioPharma, Inc.
36.89+4.30
ZURA
Zura Bio Limited
4.12+0.05